A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19

Table 2

Primary outcomes.

	Hazard ratio	value	95% CI
Discharge status (dead vs. alive)	0.53	0.042	0.29–0.97
Requirement of mechanical ventilation on discharge status	2.32	0.005	1.28–4.19